13,189 Shares in Pfizer Inc. (NYSE:PFE) Purchased by TFB Advisors LLC

TFB Advisors LLC purchased a new position in Pfizer Inc. (NYSE:PFE) in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 13,189 shares of the biopharmaceutical company’s stock, valued at approximately $358,000.

Other institutional investors have also added to or reduced their stakes in the company. Mediolanum International Funds Ltd bought a new position in shares of Pfizer during the 1st quarter valued at about $7,078,000. Pzena Investment Management LLC increased its stake in Pfizer by 181.6% in the 1st quarter. Pzena Investment Management LLC now owns 7,670,445 shares of the biopharmaceutical company’s stock worth $212,855,000 after acquiring an additional 4,947,000 shares during the last quarter. Larson Financial Group LLC grew its holdings in shares of Pfizer by 49.0% in the first quarter. Larson Financial Group LLC now owns 33,769 shares of the biopharmaceutical company’s stock valued at $937,000 after purchasing an additional 11,101 shares in the last quarter. Callan Capital LLC boosted its holdings in shares of Pfizer by 32.1% in the 1st quarter. Callan Capital LLC now owns 15,294 shares of the biopharmaceutical company’s stock worth $424,000 after purchasing an additional 3,718 shares during the period. Finally, MRA Advisory Group raised its holdings in Pfizer by 13.2% during the 1st quarter. MRA Advisory Group now owns 18,310 shares of the biopharmaceutical company’s stock valued at $508,000 after buying an additional 2,132 shares during the period. 68.36% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

PFE has been the topic of a number of analyst reports. Cantor Fitzgerald reiterated an “overweight” rating and set a $45.00 price objective on shares of Pfizer in a research report on Wednesday. Argus downgraded shares of Pfizer from a “buy” rating to a “hold” rating in a research note on Friday, March 22nd. Morgan Stanley increased their price target on Pfizer from $28.00 to $29.00 and gave the stock an “equal weight” rating in a report on Thursday, May 2nd. Finally, BMO Capital Markets reaffirmed an “outperform” rating and set a $36.00 target price (up previously from $33.00) on shares of Pfizer in a research report on Thursday, May 2nd. Nine analysts have rated the stock with a hold rating and six have given a buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $35.54.

Pfizer Stock Up 2.3 %

Shares of PFE traded up $0.63 during mid-day trading on Wednesday, hitting $28.35. 26,990,295 shares of the company traded hands, compared to its average volume of 40,022,254. The business has a 50 day moving average of $28.18 and a 200 day moving average of $27.71. The company has a market capitalization of $160.65 billion, a PE ratio of -469.59, a price-to-earnings-growth ratio of 1.10 and a beta of 0.69. The company has a quick ratio of 0.78, a current ratio of 1.05 and a debt-to-equity ratio of 0.66. Pfizer Inc. has a 1-year low of $25.20 and a 1-year high of $37.80.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Wednesday, May 1st. The biopharmaceutical company reported $0.82 earnings per share for the quarter, topping analysts’ consensus estimates of $0.56 by $0.26. The firm had revenue of $14.88 billion for the quarter, compared to analyst estimates of $13.87 billion. Pfizer had a negative net margin of 0.56% and a positive return on equity of 8.64%. The business’s quarterly revenue was down 19.5% compared to the same quarter last year. During the same quarter in the prior year, the business earned $1.23 earnings per share. Equities research analysts anticipate that Pfizer Inc. will post 2.38 EPS for the current year.

Pfizer Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 3rd. Stockholders of record on Friday, July 26th will be paid a $0.42 dividend. The ex-dividend date is Thursday, July 25th. This represents a $1.68 dividend on an annualized basis and a dividend yield of 5.93%. Pfizer’s payout ratio is -2,799.53%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.